



HAL
open science

Role of the small integrin-binding ligand N-linked glycoprotein (SIBLING), bone sialoprotein (BSP) in bone development and remodeling.

L. Malaval, J. Aubin, L. Vico

► **To cite this version:**

L. Malaval, J. Aubin, L. Vico. Role of the small integrin-binding ligand N-linked glycoprotein (SIBLING), bone sialoprotein (BSP) in bone development and remodeling.. *Osteoporosis International*, 2009, epub ahead of print. 10.1007/s00198-009-0869-2 . ujm-00374655

HAL Id: ujm-00374655

<https://ujm.hal.science/ujm-00374655>

Submitted on 9 Apr 2009

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Role of the Small Integrin Binding Ligand N-linked Glycoprotein (SIBLING), bone sialoprotein (BSP) in bone development and remodeling.

Luc Malaval^{1*}, Jane E Aubin² and Laurence Vico¹

1 : INSERM U890-LBTO, 42023 Saint-Etienne, France ; IFR 143, 42023 Saint-Etienne, France ; Université Jean Monnet, 42023 Saint-Etienne, France.

2 : Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

* : Corresponding author :

INSERM U890-LBTO

IFR 143-IFRESIS

Université Jean Monnet

Faculté de Médecine

15. rue A. Paré

42023 St Etienne Cedex 02

France

T. 33-4-77-42-14-44

Fax 33-4-77-57-55-72

E-mail: luc.malaval@univ-st-etienne.fr

Between cell and mineral - the SIBLINGs

The « small, integrin binding ligand, N-linked glycoprotein » family (SIBLINGs, [1]) group osteopontin (OPN), bone sialoprotein (BSP), dentin sialophosphoprotein (DSPP), dentin matrix protein-1 (DMP-1) and matrix extracellular glycoosphoprotein (MEPE). The genes for this family are aligned on a portion of human chromosome 4 (mouse chromosome 5), within a « Bone Gene Cluster » [2, 3] grouping other genes of bone interest. Molecular evolution studies [4, 5] suggest that SIBLINGs, along with enamelin and other proteins found in milk (caseins) and saliva (statherin), form a « Secretory Calcium binding PhosphoProteins » (SCPP) family [4], sharing as a common ancestor Hevin [6], and more precisely the long N-terminal domain that distinguishes it from the related protein SPARC (secreted protein, acidic and rich in cysteine)/Osteonectin [7]. The SCPP share a flexible structure, and many contain numerous acidic aminoacid residues, which favor interactions with crystals (review in [8]). The SIBLINGs, more specifically, have acidic pI (with the exception of MEPE), and display in their sequence a proline-rich stretch (basic), consensus sites for casein-kinase, an arginine-glycine-aspartic acid (RGD) sequence binding intergrin family receptors, and (apart for BSP) one or several ASARM (acidic serine-aspartate rich MEPE associated) peptides, which have a high affinity for hydroxyapatite and appear to be potent regulators of mineralization [9, 10]. The SIBLINGs also display a high degree of post-translational modification (phosphorylation, sulfatation and/or glycosylation) which varies for a given protein in time (cellular differentiation) and space (tissue), and directly affects their biological functions (review in [11]). In bone, the SIBLINGs are expressed by cells of the osteoblast lineage, DMP-1 and MEPE being mostly restricted to osteocytes. OPN and BSP at least are also expressed by hypertrophic chondrocytes and osteoclasts. SIBLINGs are also present in multiple non-mineralized tissues, expecially with secretory functions (salivary

glands, kidney, [12, 13]) and by cancer cells in which they favor metastatic processes, particularly targeting bone (review in [14]).

Regulators of matrix mineralization and bone remodeling

DMP1 and MEPE appear as prominent regulators of mineralization. DMP1 knockout mice display massive osteomalacia [15], at least in part indirectly, through impaired maturation of osteocytes, which is necessary to proper mineralization, and also increased levels of FGF-23 (a powerful negative regulator of phosphatemia [16]) as well as MEPE [17]. In contrast, MEPE knockout increases bone mass [18]. A major inhibitory factor of mineralisation (“Minhibin”, [19]) is the ASARM peptide (review in [9]), which is cleaved by cathepsins B and K from MEPE and DMP-1, circulates in blood and is responsible for the high levels of osteomalacia observed in hypophosphatemia [10]. The most studied of SIBLINGs, OPN (review in [20]), is a ubiquitous protein whose functions range from inflammation to lactation, and which has been called a cytokine [21]. The bones of OPN knockout mice [22] display a cell-autonomous defect of osteoclast recruitment and activity. This results in resorption defect, a higher trabecular bone mass in mutant bones, and a lack of response to challenges increasing bone loss, such as ovariectomy [23] and hindlimb unloading, a model of disuse bone loss [24]. Interacting with bone cells through both integrins (mostly $\alpha v\beta 3$) and CD44, OPN thus appears directly involved in the regulation of cell adhesion and bone remodeling. Interestingly, OPN $-/-$ bone is also hypermineralized, and lack of OPN partly compensates osteomalacia in mice with a knockout of tissue non specific alkaline phosphatase (TNALP), confirming that OPN also plays a part as a physiological inhibitor of organic matrix mineralization [25]. Considering that OPN and BSP (review in [26]) are the two major SIBLINGs expressed in bone forming osteoblasts, it is important to clarify the specificities

and redundancies in their respective functions.

The roles of BSP - insights from a mild phenotype knockout

We generated BSP knockout (BSP^{-/-}) mice through genetic recombination, and studied both their basal phenotype and their response to challenges [27]. BSP^{-/-} mice develop and grow normally, but remain smaller than their wild-type counterparts throughout life (Figure 1a, b). Cortical bone is thinner in young mutant mice (Figure 1c) and progressively increases with age to reach wild type values. BSP^{-/-} mice display early, mild matrix hypomineralization (~5% in adults), which also progressively normalizes in older mice. Previous *in vitro* data already showed that BSP promotes the formation of hydroxyapatite crystals, contrarily to OPN [28]. BSP is highly abundant in woven, primary bone [29] where it would play a direct part in mineralization, in association with an unrelated aggregating glycoprotein, bone acidic glycoprotein-75 [30, 31]. Indeed, primary marrow cultures from BSP^{-/-} bones grow normal numbers of TNALP⁺ (=osteoblast lineage) colonies but reduced numbers of mineralized nodules respective to wild type controls. The progressive recovery of mineralization degree in older BSP^{-/-} mice also suggests a role in mineralization focused on primary bone. However, BSP^{-/-} marrow cultures also display reduced expression of osteoblast-related genes, such as type I collagen, indicating that, beyond crystal nucleation, lack of BSP also affects mineralization through alterations of the osteoblast phenotype and matrix amount/composition. This confirms previous work with recombinant proteins, showing the importance of BSP, specifically the RGD containing portion, for osteoblast phenotypic regulation [32]. Osteoblast phenotype impairment could also explain why the bone formation rate (BFR) of secondary, trabecular bone of BSP^{-/-} mice is very low (Figure 1d), with reduced osteoblast surfaces and increased osteoid surfaces and thickness. We challenged the

ability of mutant mice to repair bone with a cortical defect model. After drilling a hole in the femur proximal to the knee articulation, repair was followed up through histology, MRI and microtomography. The lack of BSP significantly delayed the filling up of the defect respective to wild-type controls, confirming the impairment of bone formation (data to be published). Surprisingly with such low BFR, trabecular bone volume is higher (~30%) in 4 month old BSP^{-/-} long bones than in wild type (Figure 1c), indicating a concomitant reduction of bone resorption. Osteoclast surfaces and numbers are indeed reduced in mutant mice (Figure 1d), and impaired osteoclast differentiation from BSP^{-/-} spleen and marrow cells was confirmed in vitro [27], in accordance with previous studies [33, 34]. We then asked whether the low turnover phenotype of mutant mice could be increased by a classical challenge. BSP^{-/-} and wild type mice of both sexes were submitted to hindlimb unloading through tail suspension for 2 to 3 weeks. We found that, contrarily to the OPN knockout [24], mice lacking BSP lose bone under unloading, with increased BFR and osteoclast surfaces [27].

In conclusion, BSP knockout impairs body and long bone growth and bone repair, but induces a high trabecular bone mass with low bone turnover that is, nonetheless, responsive to mechanical challenges. These data clearly contrast with the phenotype of OPN knockout bone, and highlight the specificity of BSP roles in the bone context, and on a larger scale the nonredundancy of function of SIBLING family members in skeletal biology.

This work was funded by the Canadian Institutes of Health Research (FRN83704 to J.E. Aubin) and by the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Centre National de la Recherche Scientifique (CNRS), through both basal funding to affiliated laboratories and a collective grant within the Ingénierie Tissulaire-Biomécanique-Biomatériaux (IT2B) INSERM/CNRS cooperative program. We gratefully acknowledge additional funding from the Société Française de Rhumatologie through a PhD scholarship.

Figure 1. Bone phenotype of BSP^{-/-} mice. (a) Pictures of BSP knockout (^{-/-}) and wild type (^{+/+}) mice ; (b) whole radiography and (c) cortical 2D microtomography of isolated femurs from ^{+/+} and ^{-/-} mice ; (d) quantification of bone formation rate (BFR) and osteoclast surfaces (Oc.S/BS) in the tibial trabecular bone of ^{+/+} and ^{-/-} mice ; (e) 3D microtomographic reconstruction of trabecular bone in the metaphysis of ^{+/+} and ^{-/-} femurs. The original data were published in Malaval et al., J Exp Med 205:1145-1153 - Copyright belongs to the authors.

Bibliography


1. Fisher LW, Fedarko NS (2003) Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. *Connect Tissue Res* 44 Suppl 1:33-40.
2. Rowe PS (2000) The molecular background to hypophosphataemic rickets. *Arch Dis Child* 83:192-4.
3. MacDougall M, Simmons D, Gu TT, Dong J (2002) MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21. *Connect Tissue Res* 43:320-30.
4. Kawasaki K, Suzuki T, Weiss KM (2004) Genetic basis for the evolution of vertebrate mineralized tissue. *Proc Natl Acad Sci U S A* 101:11356-61.
5. Sire JY, Delgado S, Fromentin D, Girondot M (2005) Amelogenin: lessons from evolution. *Arch Oral Biol* 50:205-12.
6. Sullivan MM, Sage EH (2004) Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. *Int J Biochem Cell Biol* 36:991-6.
7. Bradshaw AD, Sage EH (2001) SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. *J Clin Invest* 107:1049-54.
8. Huq NL, Cross KJ, Ung M, Reynolds EC (2005) A review of protein structure and gene organisation for proteins associated with mineralised tissue and calcium phosphate stabilisation encoded on human chromosome 4. *Arch Oral Biol* 50:599-609.
9. Rowe PS (2004) The wrickkened pathways of FGF23, MEPE and PHEX. *Crit Rev Oral Biol Med* 15:264-81.

10. Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS (2008) Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. *Endocrinology* 149:1757-72.
11. Qin C, Baba O, Butler WT (2004) Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. *Crit Rev Oral Biol Med* 15:126-36.
12. Ogbureke KU, Fisher LW (2004) Expression of SIBLINGs and their partner MMPs in salivary glands. *J Dent Res* 83:664-70.
13. Ogbureke KU, Fisher LW (2005) Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). *Kidney Int* 68:155-66.
14. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. *Nat Rev Cancer* 8:212-26.
15. Ling Y, Rios HF, Myers ER, Lu Y, Feng JQ, Boskey AL (2005) DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. *J Bone Miner Res* 20:2169-77.
16. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. *Nat Genet* 38:1310-5.
17. Harris SE, Gluhak-Heinrich J, Harris MA, Yang W, Rowe PSN, Xie Y, Rios H, Zhang S, McKee MD, Bonewald LF, Feng JQ (2005) MEPE is overexpressed in osteocytes of the DMP1 (dentin matrix protein 1) null mouse, contributing to the hypophosphatemia and osteomalacia. *Journal of Bone and Mineral Research* 20:S178-S79.


18. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA (2003) Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. *J Biol Chem* 278:1998-2007.
19. Quarles LD (2003) Evidence for a bone-kidney axis regulating phosphate homeostasis. *J Clin Invest* 112:642-6.
20. Sodek J, Ganss B, McKee MD (2000) Osteopontin. *Crit Rev Oral Biol Med* 11:279-303.
21. Patarca R, Saavedra RA, Cantor H (1993) Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. *Crit Rev Immunol* 13:225-46.
22. Rittling SR, Matsumoto HN, McKee MD, Nanci A, An XR, Novick KE, Kowalski AJ, Noda M, Denhardt DT (1998) Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. *J Bone Miner Res* 13:1101-11.
23. Yoshitake H, Rittling SR, Denhardt DT, Noda M (1999) Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. *Proc Natl Acad Sci U S A* 96:8156-60.
24. Ishijima M, Rittling SR, Yamashita T, Tsuji K, Kurosawa H, Nifuji A, Denhardt DT, Noda M (2001) Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. *J Exp Med* 193:399-404.
25. Harmey D, Johnson KA, Zelken J, Camacho NP, Hoylaerts MF, Noda M, Terkeltaub R, Millan JL (2006) Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in *Akp2(-/-)* mice. *J Bone Miner Res* 21:1377-86.

26. Ganss B, Kim RH, Sodek J (1999) Bone sialoprotein. *Crit Rev Oral Biol Med* 10:79-98.
27. Malaval L, Wade-Gueye NM, Boudiffa M, Fei J, Zirngibl R, Chen F, Laroche N, Roux JP, Burt-Pichat B, Duboeuf F, Boivin G, Jurdic P, Lafage-Proust MH, Amedee J, Vico L, Rossant J, Aubin JE (2008) Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. *J Exp Med* 205:1145-53.
28. Hunter GK, Goldberg HA (1994) Modulation of crystal formation by bone phosphoproteins: role of glutamic acid-rich sequences in the nucleation of hydroxyapatite by bone sialoprotein. *Biochem J* 302 (Pt 1):175-9.
29. Gorski JP (1998) Is all bone the same? Distinctive distributions and properties of non-collagenous matrix proteins in lamellar vs. woven bone imply the existence of different underlying osteogenic mechanisms. *Crit Rev Oral Biol Med* 9:201-23.
30. Gorski JP, Wang A, Lovitch D, Law D, Powell K, Midura RJ (2004) Extracellular bone acidic glycoprotein-75 defines condensed mesenchyme regions to be mineralized and localizes with bone sialoprotein during intramembranous bone formation. *J Biol Chem* 279:25455-63.
31. Midura RJ, Wang A, Lovitch D, Law D, Powell K, Gorski JP (2004) Bone acidic glycoprotein-75 delineates the extracellular sites of future bone sialoprotein accumulation and apatite nucleation in osteoblastic cultures. *J Biol Chem* 279:25464-73.
32. Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK, Goldberg HA (2007) Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. *Bone* 41:462-73.
33. Raynal C, Delmas PD, Chenu C (1996) Bone sialoprotein stimulates in vitro bone resorption. *Endocrinology* 137:2347-54.

34. Valverde P, Tu Q, Chen J (2005) BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. *J Bone Miner Res* 20:1669-79.



d



e

